MRPMedical Research and Practice2993-96902993-9704Art and Design10.61369/MRP.2025080034Article疏肝和胃方含药血清对食管上皮细胞损伤的干预作用https://artdesignp.com/journal/MRP/3/8/10.61369/MRP.2025080034汪陆叶,孙永顺2025382025-08-20目的：探讨疏肝和胃方含药血清对GERD 食管上皮细胞损伤的干预作用。方法：实验分四组，除正常组外，其余三组予胰蛋白酶刺激HEEC 构建GERD 体外细胞模型。正常组和模型组予生理盐水含药血清孵育，中药组予疏肝和胃方含药血清孵育，西药组予雷贝拉唑肠溶胶囊含药血清孵育。24h 后通过ELISA 方法检测IL-8、IL-1β 和PAF，WB 检测PAR-2、Claudin1和Claudin4。所得结果采用SPSS26.0 统计分析。结果：与正常组相比，模型组PAR-2、IL-8、IL-1β 和PAF 显著增加（P<0.05），Claudin1和Claudin4显著降低（P<0.05）；与模型组相比，中西药组PAR-2、IL-8和PAF 均显著降低（P<0.05），中药组IL-1β 显著降低（P<0.05），西药组IL-1β 呈降低趋势（P>0.05），且中药组表达均低于西药组，其中中西药组IL-8和PAF 表达有统计学差异（P<0.05），中西药组Claudin1 显著升高（P<0.05），中药组Claudin4 显著升高（P<0.05），西药组Claudin4 呈升高趋势（P>0.05），且中药组表达均显著高于西药组（P<0.05）。结论： 疏肝和胃方可以通过降低PAR-2、IL-8、 IL-1β 和PAF 的表达，增加Claudin1和Claudin4蛋白的表达，改善食管黏膜炎性损伤，有效的治疗GERD，且疗效优于雷贝拉唑。GERD,PAR-2,炎性因子,Claudin,疏肝和胃方

[1]Eusebi LH, Ratnakumaran R, Yuan Y, et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018 Mar;67(3):430-440.[2] 汪忠镐, 吴继敏, 胡志伟, 等. 中国胃食管反流病多学科诊疗共识[J]. 中华胃食管反流病电子杂志,2020,7(01):1-28.[3]DeVault KR, Castell DO; American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol.2005 Jan;100(1):190-200.[4]Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut. 2009 Feb;58(2):295-309.[5] 李榕萍, 曹雯, 张靖娟, 等. 疏肝健脾和胃方对难治性胃食管反流病患者食管黏膜PAR2 及TRPV1 蛋白表达的影响[J]. 福建医药杂志,2017,39(02):80-82.[6]Xiaopeng B, Tanaka Y, Ihara E, et al. Trypsin induces biphasic muscle contraction and relaxation via transient receptor potential vanilloid 1 and neurokinin receptors 1/2 in porcine esophageal body. Eur J Pharmacol. 2017 Feb 15;797:65-74.[7]Shan J, Oshima T, Chen X, et al. Trypsin impaired epithelial barrier function and induced IL-8 secretion through basolateral PAR-2: a lesson from a stratified squamous epithelial model. Am J Physiol Gastrointest Liver Physiol. 2012 Nov 15;303(10):G1105-12.[8]Souza RF. Bringing GERD Management up to PAR-2. Am J Gastroenterol. 2010 Sep;105(9):1944-6.[9]Ma J, Altomare A, de la Monte S, et al. HCl-induced inflammatory mediators in esophageal mucosa increase migration and production of H2O2 by peripheral blood leukocytes. Am J Physiol Gastrointest Liver Physiol. 2010 Sep;299(3):G791-8.[10]Harnett KM, Rieder F, Behar J, et al. Viewpoints on Acid-induced inflammatory mediators in esophageal mucosa. J Neurogastroenterol Motil. 2010 Oct;16(4):374-88.[11]Kim JJ, Kim N, Park JH, et al. Comparison of Tight Junction Protein-Related Gene mRNA Expression Levels between Male and Female Gastroesophageal Reflux Disease Patients. Gut Liver. 2018 Jul 15;12(4):411-419.[12]Chu CL, Zhen YB, Lv GP, et al. Microalterations of esophagus in patients with non-erosive reflux disease: in-vivo diagnosis by confocal laser endomicroscopy and its relationship with gastroesophageal reflux [J].Am J Gastroenterol. 2012, 107(6): 864-874.[13]Hashimoto I, Oshima T. Claudins and Gastric Cancer: An Overview. Cancers (Basel). 2022 Jan 7;14(2):290.